NSABP

NSABP
Name	NSABP
Formation	1946
Headquarters	Pittsburgh, Pennsylvania
Type	Medical research consortium
Purpose	Clinical trials in breast and colorectal cancer
Affiliations	National Cancer Institute, ECOG-ACRIN Cancer Research Group, American College of Surgeons, American Society of Clinical Oncology

NSABP is a cooperative clinical trials group founded to study therapies for breast and colorectal malignancies through multi-center randomized trials. It has conducted landmark randomized controlled trials and translational studies that influenced surgical practice, systemic therapy, and adjuvant treatment paradigms across oncology. The group has interacted extensively with federal health agencies, academic centers, and professional societies to translate trial results into practice.

History

The group began after World War II with investigators at institutions such as University of Pennsylvania, Harvard Medical School, Mayo Clinic, Johns Hopkins Hospital, and Memorial Sloan Kettering Cancer Center collaborating on comparative trials. Early work paralleled initiatives by the National Institutes of Health and the National Cancer Institute to standardize multi-institutional research in the mid-20th century. During the 1970s and 1980s, leaders affiliated with Dana-Farber Cancer Institute, Stanford University School of Medicine, University of California, San Francisco, and Columbia University Irving Medical Center expanded the portfolio to include adjuvant chemotherapy and radiation trials. Subsequent decades saw coordination with cooperative groups such as CALGB and RTOG and integration with translational programs at institutions like Fred Hutchinson Cancer Center and Sloan Kettering Institute.

Organization and governance

The consortium is governed by a steering committee and executive officers drawn from academic centers including University of Pittsburgh Medical Center, Duke University School of Medicine, Yale School of Medicine, and University of Michigan. Regulatory oversight has involved the Food and Drug Administration, institutional review boards at centers like Massachusetts General Hospital, and data safety monitoring boards that include representation from American Society of Clinical Oncology and American College of Surgeons. Funding streams have combined grants from the National Cancer Institute, philanthropic support from foundations such as Susan G. Komen for the Cure and collaboration with cooperative groups like EORTC and SWOG. Scientific leadership often comprises investigators who have held positions at NCI Cancer Centers Program institutions and who have served on panels for organizations such as U.S. Preventive Services Task Force.

Major clinical trials and contributions

Investigators contributed pivotal trials that compared mastectomy and breast-conserving surgery in collaboration with centers like Brigham and Women's Hospital and University of Chicago Medicine, influencing surgical standards endorsed by societies such as American Society of Breast Surgeons. Landmark randomized trials tested adjuvant regimens involving agents developed by pharmaceutical companies and evaluated by regulatory bodies including the FDA; results were adopted in guidelines from NCCN and ASCO. Trials assessing tamoxifen and aromatase inhibitors intersected with work at MD Anderson Cancer Center and Vanderbilt University Medical Center, while chemotherapy sequencing studies involved partners like Northwestern Memorial Hospital and Cleveland Clinic. The group’s colorectal cancer studies connected investigators from Roswell Park Comprehensive Cancer Center and University of Texas MD Anderson Cancer Center, affecting recommendations by organizations such as American Society of Clinical Oncology and European Society for Medical Oncology.

Methodology and research focus

The consortium emphasized randomized controlled trial design, central pathology review with reference laboratories such as those at Memorial Sloan Kettering Cancer Center, and specimen banking for correlative science with laboratories at Broad Institute and Cold Spring Harbor Laboratory. Statistical methods drew on expertise from biostatistics groups at Harvard T.H. Chan School of Public Health, Johns Hopkins Bloomberg School of Public Health, and University of Washington, using stratification and intention-to-treat principles consistent with contemporary standards endorsed by CONSORT-aligned panels and guideline committees at National Comprehensive Cancer Network. Translational endpoints incorporated biomarkers discovered at centers like Fred Hutchinson Cancer Center, Scripps Research, and Dana-Farber Cancer Institute, enabling pharmacogenomic analyses and molecular subtyping analogous to work published from The Cancer Genome Atlas consortium.

Impact on cancer treatment guidelines

Results influenced practice guidelines issued by National Comprehensive Cancer Network, American Society of Clinical Oncology, and panels convened by the U.S. Preventive Services Task Force. Surgical trial outcomes informed position statements from American College of Surgeons and specialty societies such as Society of Surgical Oncology and American Society of Breast Surgeons. Adjuvant therapy findings fed into chemotherapy and endocrine therapy algorithms cited in standards from NCCN and consensus statements authored with contributors from European Society for Medical Oncology. Health policy and coverage determinations by payers and agencies, including analyses used by the Centers for Medicare & Medicaid Services, referenced trial evidence from the group when defining medically necessary interventions.

Collaborations and partnerships

The consortium partnered with cooperative groups including ECOG-ACRIN Cancer Research Group, SWOG, Alliance for Clinical Trials in Oncology, and EORTC to coordinate large multi-national trials. Academic partnerships included Yale School of Medicine, University of Pennsylvania Perelman School of Medicine, and Columbia University Vagelos College of Physicians and Surgeons, while translational collaborations involved Broad Institute, Cold Spring Harbor Laboratory, and pharmaceutical research units at companies like Pfizer and Novartis. Data-sharing and biobanking initiatives linked to programs at dbGaP, repositories associated with National Cancer Institute, and cooperative efforts with international registries such as those maintained by International Agency for Research on Cancer.

Category:Clinical trial groups